Navigation Links
Encision Reports 10% Product Revenue Increase in Third Quarter of Fiscal Year 2013 Results
Date:1/28/2013

BOULDER, Colo., Jan. 28, 2013 /PRNewswire/ -- Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, today announced financial results for its fiscal 2013 third quarter ended December 31, 2012. 

The Company posted quarterly product revenue of $2.955 million and quarterly service revenue of $100 thousand for a quarterly net loss of $82 thousand, or $(0.01) per share. These results compare to product revenue of $2.689 million and service revenue of $479 thousand for a net loss of $81 thousand, or $(0.01) per share, in the year-ago quarter. Gross margin was 54.5 percent compared to 55 percent in the year-ago quarter.

The Company posted nine months product revenue of $8.566 million and nine months service revenue of $464 thousand for a nine months net loss of $337 thousand, or $(0.04) per share. These results compare to product revenue of $8.352 million and service revenue of $1.266 million for a net loss of $570 thousand, or $(0.09) per share, in the year-ago nine months. Gross margin was 56 percent compared to 53 percent in the year-ago nine months. In the year-ago nine months, our margin was lower due to a one-time charge of $430 thousand for a voluntary recall of a certain electrode product.

"We were pleased that our product revenue grew ten percent for the third quarter over last year's third quarter and five percent over this year's second quarter," said Fred Perner , President and CEO. "As we previously announced, our service revenue continues to lag last year's pace due to a project that was phased out by a strategic partner at the beginning of this fiscal year. Additionally, we continued to make investments in our quality platform and product development initiatives. In the third quarter, our inventory levels increased as we expect to introduce new products in our fourth
'/>"/>

SOURCE Encision Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Encision Reports Second Quarter of Fiscal Year 2013 Results
2. Encision Reports First Quarter of Fiscal Year 2013 Results
3. Education and Collaboration Key to Continued Progress in Fighting Rogue Online Prescription Drug Sellers, Reports NABP
4. Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
5. Cepheid Reports Fourth Quarter And Full Year 2012 Results
6. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
7. Hill-Rom Reports Fiscal First Quarter Results; Updates 2013 Financial Outlook For R&D Tax Credit Reinstatement
8. Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2013
9. MGC Diagnostics Corporation Reports Fourth Quarter and Fiscal Year 2012 Operating Results
10. Avanir Pharmaceuticals Reports Fiscal 2012 Fourth Quarter And Year-End Financial And Business Results
11. Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... 18, 2014  Spring Bank Pharmaceuticals, Inc., a ... treatment of RNA viruses, today announced a research ... for animal testing of the Company,s lead compound, ... "Special Pathogens," against which currently there are no ... Spring Bank,s proprietary Small Molecule Nucleic Acid ...
(Date:9/18/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced the first presentation of positive safety and ... Investigation of Collagenase Optimizing the Resolution of Dupuytrens) ... histolyticum (CCH) for the treatment of two Dupuytren,s ... the study examined expanded flexibility with timing of ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... GA (PRWEB) September 18, 2014 Ben ... the Alex Ormond, Jr. Leadership Award by the Savannah ... improving healthcare and wellness throughout the nation and especially ... receive this award,” said Ben. “The Savannah Science Seminar ... 65 years and multiple generations have gone through the ...
(Date:9/18/2014)... have developed a new method to study Ebola virus ... Wildlife Conservation Society (WCS)-led research, published today in the ... use of fecal samples from wild great apes to ... virus. This represents a new tool for performing large, ... Ebola virus is studied and improve our understanding of ...
(Date:9/18/2014)... (September 18, 2014) The National Institutes of Health ... a four-year, $1.3 million grant to the Los Angeles ... research and development of a vaccine to protect patients ... Staphylococcus aureus (MRSA). , The National ... NIH awarded the grant to LA BioMed infectious disease ...
(Date:9/18/2014)... trying to develop tools that would allow them to ... moment a neuron fires to the resulting behavior in ... are working to develop a range of new tools ... one such tool that provides a new way of ... worka collaboration between Viviana Gradinaru (BS ,05), assistant professor ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... Brophy Marcus HealthDay Reporter , WEDNESDAY, Oct. 5 ... after a kidney transplant allows some patients to cast away ... new organ, according to a small new study from the ... in the United States and while they can greatly improve ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. 5 ... tip-top health may have a greater risk of developing dementia ... Oct. 5 issue of the journal Neurology . ... simple tool for doctors to determine a person,s risk of ...
... WEDNESDAY, Oct. 5 (HealthDay News) -- The death toll from ... risen to 18, and a total of 100 people have ... Control and Prevention reported late Tuesday. The agency said ... 14, more cases might still emerge since Listeria monocytogenes ...
... from Mount Sinai School of Medicine have found high ... (AGEs) in infants. Excessive food AGEs, through both maternal ... children,s risk for diseases such as diabetes from a ... adults found that cutting back on processed, grilled, and ...
... (HealthDay News) -- Scientists who taught monkeys to use their ... virtual body) and to identify the texture of virtual objects ... for people who,ve suffered crippling spinal injuries. "Someday in ... technology not only to move their arms and hands and ...
... (October 5, 2011)Prostate cancer is the most common cancer ... the second leading cause of cancer-related deaths in this ... their prostate, followed by radiation therapy applied to their ... once situated. The most common technique of ...
Cached Medicine News:Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 3Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 4Health News:Gauging General Health as 'Poor' May Point to Dementia Risk 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 3Health News:New study shows inflammatory food toxins found in high levels in infants 2Health News:New study shows inflammatory food toxins found in high levels in infants 3Health News:Monkeys Use Brain Power, Not Hands, to 'Move' Virtual Objects 2Health News:Fox Chase researchers improve accuracy of IMRT delivery in post-prostatectomy patients 2Health News:Fox Chase researchers improve accuracy of IMRT delivery in post-prostatectomy patients 3
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
Inquire...
Medicine Products: